Contents
Key findings
- 1Compounded semaglutide is made by a pharmacy, not by the drug maker, and the FDA does not check it for safety, effectiveness or quality before it is sold.
- 2Compounding copies of these drugs was mostly allowed only because they were in shortage; those shortages are now over (tirzepatide in late 2024, semaglutide in February 2025).
- 3The FDA has received reports of dosing errors with compounded semaglutide, some serious enough to send people to hospital.
- 4Some newer ingredients, like retatrutide and cagrilintide, cannot be used in compounding at all under federal law.
- 5Products labeled "for research use only" but sold for people to inject are unapproved drugs of unknown quality.
Evidence level
The safety concerns here are documented by the FDA on its own page about unapproved GLP-1 drugs, verified against that source. Compounded versions are not reviewed by the FDA for safety, effectiveness or quality.
Regulatory status
The approved products (Ozempic, Wegovy, Rybelsus; Mounjaro, Zepbound) are FDA-approved. Compounded copies are not FDA-approved. The drug shortages that briefly allowed widespread compounding have been declared over.
Compounded semaglutide is sold as a cheaper version of Ozempic or Wegovy. It sounds like the same drug at a better price. The FDA's own guidance says the truth is more complicated - and, in some cases, risky. Here it is in plain terms.
First, what "compounded" means
A compounded drug is one that a pharmacy mixes itself, rather than one made and packaged by the original drug company. Compounding has a real, useful role - for example, making a liquid version for someone who cannot swallow pills.
But there is one thing a compounded drug is not: FDA-approved. The FDA does not check compounded drugs for safety, how well they work, or their quality before they are sold[1]. That review is exactly what the brand-name products went through and the compounded copies did not.
Why compounded semaglutide became common - and why that changed
When a drug is in short supply, the rules let pharmacies make copies so patients are not left without treatment. Semaglutide and tirzepatide were both in shortage for a while, which is why compounded versions spread through telehealth websites.
Those shortages are now over. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025. Once a shortage ends, the main reason that allowed wide compounding goes away[1].
What the FDA is worried about
The FDA lists several specific problems with compounded GLP-1 drugs[1].
Dosing mistakes. The approved products come in a pen that gives a set dose. Many compounded versions come in a vial, and the patient (or a clinician) has to measure the dose with a syringe. The FDA has received reports of dosing errors this way - some serious enough to send people to hospital. Reports also involved doses higher than the approved product allows.
Drugs arriving warm. Injectable GLP-1 drugs need to stay cold, as the package insert says. The FDA has had complaints of compounded products showing up warm or with too little ice. It advises not using any injectable GLP-1 drug that arrives warm, because heat can wreck the drug's quality.
Ingredients that are not allowed. Some newer weight-loss ingredients - retatrutide and cagrilintide - cannot be used in compounding at all under federal law. They are not part of any approved drug and have not been shown to be safe and effective. The FDA has warned telehealth companies and ingredient suppliers about selling them.
"Research use only" labels. The FDA specifically warns about products labeled "for research purposes" or "not for human consumption" that are still sold to people to inject, with dosing instructions. These are unapproved drugs of unknown quality. (We cover this labeling trick in detail in our certificate of analysis article.)
Warning signs the FDA tells consumers to watch for
If you are looking at a telehealth seller, the FDA says treat these as red flags[1]:
- It claims the compounded drug is "the same as" the FDA-approved drug.
- Prices look too good to be true, or come with steep discounts.
- The medicine looks different from what you got before, or arrives in damaged packaging with no instructions.
- No licensed doctor reviews you before you get the medicine, or is available afterward for questions.
- The label has spelling errors, a wrong pharmacy address, or a pharmacy name that seems fake.
The safer path
The FDA's own advice is simple: get a prescription from your doctor and fill it at a state-licensed pharmacy. Compounded drugs are meant for cases where an approved product cannot meet a patient's need - not as a default cheaper swap[1].
The bottom line
Compounded semaglutide is not a discount version of the same reviewed product. It is a different thing: a pharmacy-mixed copy the FDA has not checked, no longer riding on a shortage rule, and linked by the FDA to real dosing and quality problems. That does not make every compounded dose dangerous - but it does make "same drug, lower price" the wrong way to think about it.
Where to go next
- Counterfeit and fake GLP-1 products: how to spot them
- FDA-approved, off-label, investigational and unapproved peptides
- GLP-1 peptides: established uses versus emerging research
- Semaglutide profile
Frequently asked questions
- Is compounded semaglutide the same as Ozempic or Wegovy?
- No. Ozempic and Wegovy are FDA-approved products made by the drug company. Compounded semaglutide is mixed by a pharmacy and is not checked by the FDA for safety, effectiveness or quality before it is sold.
- Is compounded semaglutide legal now?
- Compounding copies of these drugs was mostly allowed because they were in shortage. Those shortages are over, so that reason no longer applies. A pharmacy can still compound in narrow cases, but the wide access that existed during the shortage has ended.
- What are the main risks the FDA points to?
- Dosing errors (some serious enough for a hospital visit), drugs arriving warm because they were not kept cold in shipping, fake or mislabeled products, and unapproved ingredients being sold.
- What about compounded tirzepatide?
- The same picture applies. Its shortage was declared over first, in late 2024, and the FDA lists it alongside semaglutide in its safety warnings.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss U.S. Food and Drug Administration, 2026.
Regulatory source
Result: Compounded GLP-1 drugs are not FDA-reviewed for safety, effectiveness or quality. FDA reports dosing errors (some requiring hospitalization), poor cold-chain handling, fraudulent labels, retatrutide/cagrilintide barred from compounding, and 'research use only' products sold for human use.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
